Following a $90 million Series C financing round led by Johnson & Johnson Innovation earliert this year, Bright Peak Therapeutics announced that the first patient was dosed in its Phase 1/2a trial evaluating BPT567. The study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors..

在强生创新公司（Johnson＆Johnson Innovation）今年早些时候领导的一轮9000万美元的C系列融资之后，Bright Peak Therapeutics宣布，第一名患者在评估BPT567的1/2a期试验中服用了药物。。。

Using innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is developing a pipeline of first-in-class multifunctional molecules. The company’s lead program, BPT567, is designed to combine two key immuno-stimulatory mechanisms of action into a single molecule, including coordinated PD-1/PD-L1 checkpoint blockade in tandem with the targeted delivery of IL-18 to T cells within the tumor microenvironment..

。该公司的领先项目BPT567旨在将两种关键的免疫刺激作用机制结合到一个分子中，包括协调的PD-1/PD-L1检查点阻断，以及将IL-18靶向递送至肿瘤微环境中的T细胞。。

IL-18 is known as a master regulator of innate and adaptive immunity, and as driver of the host immune response to cancer. Preclinical studies have shown that BPT567 mediates potent, synergistic anti-tumor activity superior to PD-1 blockade alone, with activity in both PD-1-sensitive and PD-1-resistant tumor models..

IL-18被认为是先天性和适应性免疫的主要调节剂，也是宿主对癌症免疫反应的驱动因素。临床前研究表明，BPT567介导的有效协同抗肿瘤活性优于单独的PD-1阻断剂，在PD-1敏感和PD-1耐药的肿瘤模型中均具有活性。。

While PD-1 inhibitors have revolutionized cancer immunotherapy, Bright Peak is actively investigating whether the multifunctional biology of BPT567 could not only translate to enhanced efficacy compared to PD-1/PD-L1 blockade alone in indications where checkpoint inhibitors have been approved, but also demonstrate activity in settings where checkpoint inhibitors have not worked to date or in patients who have progressed or recurred despite prior checkpoint inhibitor therapy, all of which represent major areas of unmet need for patients with cancer. .

虽然PD-1抑制剂彻底改变了癌症免疫治疗，但Bright Peak正在积极研究BPT567的多功能生物学是否不仅可以在检查点抑制剂已被批准的适应症中与单独的PD-1/PD-L1阻断相比转化为增强的功效，而且还可以在检查点抑制剂迄今为止尚未起作用的环境中或在先前检查点抑制剂治疗的进展或复发的患者中表现出活性，所有这些都代表了癌症患者未满足需求的主要领域。。

“The dosing of the first patient in this trial marks a significant and exciting milestone in our mission to provide patients with advanced solid tumors with a potentially transformative PD-1 based treatment option,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak.

Bright Peak首席执行官弗雷德里克·维克隆德（FredrikWiklund）表示：“这项试验中第一名患者的给药标志着我们为晚期实体瘤患者提供潜在的基于PD-1的治疗选择的使命中一个重要而令人兴奋的里程碑。”。

Jon Wigginton, M.D., President of Research and Development at Bright Peak, added, “Preclinical studies of BPT567 have demonstrated very encouraging results and we are eager to further explore BPT567’s dual mechanism, which we believe could have the potential to deliver impactful anti-tumor efficacy,  including for patients who have not responded to conventional PD-1 inhibitors alone, and in new indications where current PD-1s are not approved.

Bright Peak研究与开发总裁Jon Wigginton医学博士补充道：“BPT567的临床前研究已经证明了非常令人鼓舞的结果，我们渴望进一步探索BPT567的双重机制，我们认为它可能具有产生有效抗肿瘤功效的潜力，包括对单独使用常规PD-1抑制剂没有反应的患者，以及目前PD-1未被批准的新适应症。

We look forward to advancing this important Phase 1/2a study in collaboration with participating patients, and leading immuno-oncology centers.”.

我们期待着与参与患者和领先的免疫肿瘤学中心合作，推进这项重要的1/2a期研究。”。

Bright Peak’s chemical protein synthesis technology was initially developed by its Founders Vijaya Pattabiraman and Jeffrey Bode at ETH Zürich and the company was seeded and launched by Versant Ventures at the firm’s Ridgeline Discovery laboratories. The company is based at the Switzerland Innovation Park Basel Area Main Campus in Allschwil (BS) and San Diego, CA..

Bright Peak的化学蛋白质合成技术最初是由其创始人Vijaya Pattabiraman和Jeffrey Bode在ETH Zürich开发的，该公司由Versant Ventures在该公司的Ridgeline Discovery laboratories播种并启动。该公司位于瑞士创新园巴塞尔地区主校区，位于奥尔施维尔（BS）和加利福尼亚州圣地亚哥。。

(Press release / SK)

（新闻稿/SK）

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send